Relmada licenses NDV-01 from Trigone for $3.5M + 3M shares; Phase 2 data at AUA April 2025

RELMADA THERAPEUTICS, INC.

Upfront: $3.5M cash + 3,017,420 shares (10% of outstanding) for exclusive worldwide rights (ex-India, Israel, S. Africa).
Up to $200M in development/regulatory/sales milestones + 3% royalty on net sales.
NDV-01 is sustained-release gemcitabine/docetaxel for NMIBC; Phase 2 topline data at AUA April 26-29, 2025.
Shares locked up for 12 months; Trigone must vote as board recommends.
Relmada must spend ≥$5M/year on R&D/commercialization from 2026; Trigone can terminate if not.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.